Pramipexole: Research, Dosing, and Where to Buy in 2026
A research-first profile for Pramipexole (prami), aggregating mechanism notes, transcript dosing mentions, vendor recommendations, and PubMed-indexed literature without presenting medical guidance.
Pramipexole is a research compound profiled here from named-expert transcripts and peer-reviewed literature, without medical guidance. As of July 2026, The Peptide Wiki aggregates 8 PubMed-cited papers for Pramipexole, each linked to its source.
- Also indexed as prami.
- 0 aggregated dosing-protocol mentions from source transcripts.
- 8 PubMed-indexed citations listed in the research table below.
- 0 vendor recommendations captured from named experts.
What is Pramipexole?
Research compound aggregated from creator and literature mentions. No direct disease-treatment claims are made on this page.
Pramipexole Dosing Protocols
The entries below are transcript-derived dosing mentions. They are preserved for research context and are not medical advice.
No transcript-derived dosing mentions in current source set.
Where to Buy Pramipexole in 2026
No tracked vendor recommendations for Pramipexole yet. See our vendor directory.
Side Effects and Safety
Anecdotal reports and study-level observations vary by route, dose, and individual. This page does not provide medical advice. Consult a qualified clinician before any research use.
User Reviews
User reviews aggregator coming Q3 2026 (Reddit + YouTube comments + Discord research notes). Until then, see the expert quote section above and PubMed citations below.
Research Efficacy Snapshot
Published efficacy percentages cited in PubMed trials and named-expert reports about Pramipexole. Each line links to the original source.
- "About 30% of patients with depression treated with antidepressant medication do not respond sufficiently to the first agents used." · Browning M et al, 2025 PubMed
- "84 (56%) participants were female and 66 (44%) were male and the mean age of participants was 44·9 years (SD 14·0)." · Browning M et al, 2025 PubMed
- "Adjusted mean decrease from baseline to week 12 of the QIDS-SR16 total score was 6·4 (SD 4·9) for the pramipexole group and 2·4 (4·0) for the placebo group; the mean difference between groups was -3·91 (95% CI -5·37 to -2·45; p<0·0001)." · Browning M et al, 2025 PubMed
- "Termination of trial treatment due to adverse events was more frequent in the pramipexole group (15 participants [20%]) than in the placebo group (four participants [5%]), with reported adverse events consistent with known side-effects of pramipexole, in particular nausea, headache, and sleep disturbance or somnolence." · Browning M et al, 2025 PubMed
- "2.1 (5.1)]: a medium-sized (d = -0.72) but not statistically significant difference (95% confidence interval -0.4 to 6.3; p = 0.087)." · McAllister-Williams H et al, 2025 PubMed
- "Patients with bipolar disorder have symptoms (depression or elevated mood) around 50% of the time and mostly these are depressive." · McAllister-Williams H et al, 2025 PubMed
- "From the synthesis of all six selected trials, a significant mean change from baseline in the PDQ-39 total score of -2.49 (95% CI, -3.43 to -1.54; p < 0.0001) was observed with pramipexole compared with placebo." · Li T et al, 2022 PubMed
- "A trend toward improvement in QoL was consistently observed among patients who received optimal doses of pramipexole (≥ 80% of the study population on 1.5 mg dosage), regardless of disease severity (advanced versus early) or baseline QoL levels." · Li T et al, 2022 PubMed
- "The first RCT showed a significantly higher response compared to placebo (67% vs 20%), but not for remission (20% vs." · Dionys V et al, 2021 PubMed
- "A second RCT reported higher response and remission results with pramipexole compared to placebo (60% vs." · Dionys V et al, 2021 PubMed
Research and Studies
8 PubMed-indexed papers reference Pramipexole. Top 8 shown.
Legal Status
Pramipexole is presented here as a research compound. FDA approval status, scheduling, WADA status, and state-specific telehealth rules may apply. Always verify current regulatory status. Last verified: 2026-07-09.
Frequently Asked Questions
Is Pramipexole FDA-approved?
Pramipexole is presented on this page as a research compound. FDA approval status, scheduling, and state-specific rules may apply and change. Verify current regulatory status before any decision.
How much research has been published on Pramipexole?
8 PubMed-indexed paper(s) reference Pramipexole in our current research feed. See the Research and Studies section above for citations.